The Leukemia-associated Mll-Ell Oncoprotein Induces Fibroblast Growth Factor 2 (Fgf2)-dependent Cytokine Hypersensitivity in Myeloid Progenitor Cells*

C. Shah,L. Bei,Hao Wang,L. Platanias,E. Eklund
DOI: https://doi.org/10.1074/jbc.M113.496109
IF: 5.485
2013-10-02
Journal of Biological Chemistry
Abstract:Background: MLL fusion proteins, including Mll-Ell, induce overexpression of HoxA9 and HoxA10 in the bone marrow. Results: Mll-Ell induces HoxA9-and HoxA10-dependent FGF2 transcription. Autocrine production of Fgf2 contributes to cytokine hypersensitivity in Mll-Ell expressing myeloid progenitor cells. Conclusion: Mll-Ell induces Fgf2 production by myeloid progenitors and differentiating myeloid cells. Significance: Proliferative effects of Fgf2 may influence the pathogenesis of leukemias with MLL gene translocations. The subset of acute myeloid leukemias (AML) with chromosomal translocations involving the MLL gene have a poor prognosis (referred to as 11q23-AML). The MLL fusion proteins that are expressed in 11q23-AML facilitate transcription of a set of HOX genes, including HOXA9 and HOXA10. Because Hox proteins are transcription factors, this suggests the possibility that Hox target genes mediate the adverse effects of MLL fusion proteins in leukemia. Identifying such Hox target genes might provide insights to the pathogenesis and treatment of 11q23-AML. In the current study we found that Mll-Ell (an MLL fusion protein) induced transcriptional activation of the FGF2 gene in a HoxA9- and HoxA10-dependent manner. FGF2 encodes fibroblast growth factor 2 (also referred to as basic fibroblast growth factor). Fgf2 influences proliferation and survival of hematopoietic stem cells and myeloid progenitor cells, and increased Fgf2-expression has been described in AMLs. We determined that expression of Mll-Ell in myeloid progenitor cells resulted in autocrine production of Fgf2 and Fgf2-dependent cytokine hypersensitivity. Therefore, our results implicated increased Fgf2 expression in progenitor proliferation and expansion in 11q23-AML. Because small molecule inhibitors of Fgf-receptors are in human clinical trials, this suggested a potential therapeutic approach to this treatment refractory leukemia.
What problem does this paper attempt to address?